Physician profile
P Ronjon Paul
NPI 1861460693
$908,077.76
in general payments reported to CMS, 2019-2025
7 companies · $60K in 2025
The $60K reported for 2025 was more than what 89% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171K · 2020: $275K · 2021: $187K · 2022: $72K · 2023: $78K · 2024: $64K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $194K · Consulting Fee: $2,750 · Food and Beverage: $2,733 · Travel and Lodging: $2,643 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $193,838.21 |
| Consulting Fee | $2,750.00 |
| Food and Beverage | $2,733.04 |
| Travel and Lodging | $2,642.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $161.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $783,683.55 | 2019-2023 | Maxcess, Cohere, Tlif |
| Globus Medical, INC. | $123,929.54 | 2024-2025 | Cohere, Tlif, Maxcess |
| Providence Medical Technology, INC. | $161.75 | 2024 | |
| Medtronic, INC. | $155.62 | 2023 | Mazor X System |
| Si-Bone, INC. | $78.29 | 2021 | |
| Amgen INC. | $45.06 | 2025 | Evenity |
| Cerapedics INC. | $23.95 | 2024 | I-Factor Peptide Enhanced Bone Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw P Ronjon Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.